Skip to main content
Top
Published in: Indian Journal of Thoracic and Cardiovascular Surgery 6/2023

22-09-2023 | Aortic Valve Replacement | Critical Appraisal of Trials

Native aortic valve regurgitation: TAVR’s place in the PANTHEON

Author: Pradeep Narayan

Published in: Indian Journal of Thoracic and Cardiovascular Surgery | Issue 6/2023

Login to get access

Abstract

The PANTHEON (Performance of Currently Available traNscaTHEter Aortic Valve Platforms in Inoperable Patients With Pure Aortic regurgitatiON of a native valve) study examined transcatheter aortic valve replacement in patients with severe pure native aortic valve regurgitation. With a real-world dataset from 16 centres in Europe and the USA, the study encompassed 201 patients. The major complications included valve embolization or migration in 12.4%, moderate to severe aortic regurgitation in 9.5% cases and need for permanent pacemaker in 22.3% cases. Self-expanding and balloon-expandable devices demonstrated similar outcomes. Those experiencing valve embolization or migration had higher 1-year adverse event rates.
Literature
1.
go back to reference Poletti E, De Backer O, Scotti A, Costa G, Bruno F, Fiorina C, et al. Transcatheter aortic valve replacement for pure native aortic valve regurgitation: the PANTHEON International Project. JACC Cardiovasc Interv. 2023;16:1974–85.CrossRefPubMed Poletti E, De Backer O, Scotti A, Costa G, Bruno F, Fiorina C, et al. Transcatheter aortic valve replacement for pure native aortic valve regurgitation: the PANTHEON International Project. JACC Cardiovasc Interv. 2023;16:1974–85.CrossRefPubMed
2.
go back to reference VARC-3 WRITING COMMITTEE, Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42:1825–57. VARC-3 WRITING COMMITTEE, Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42:1825–57.
3.
go back to reference Vora AN, Sreenivasan J, Forrest JK. Progressing forward in transcatheter aortic valve replacement for pure aortic regurgitation. JACC Cardiovasc Interv. 2023;16:1986–9.CrossRefPubMed Vora AN, Sreenivasan J, Forrest JK. Progressing forward in transcatheter aortic valve replacement for pure aortic regurgitation. JACC Cardiovasc Interv. 2023;16:1986–9.CrossRefPubMed
4.
go back to reference Jerez-Valero M, Urena M, Webb JG, Tamburino C, Munoz-Garcia AJ, Cheema A, et al. Clinical impact of aortic regurgitation after transcatheter aortic valve replacement: insights into the degree and acuteness of presentation. JACC Cardiovasc Interv. 2014;7:1022–32.CrossRefPubMed Jerez-Valero M, Urena M, Webb JG, Tamburino C, Munoz-Garcia AJ, Cheema A, et al. Clinical impact of aortic regurgitation after transcatheter aortic valve replacement: insights into the degree and acuteness of presentation. JACC Cardiovasc Interv. 2014;7:1022–32.CrossRefPubMed
5.
go back to reference Daneault B, Koss E, Hahn RT, Kodali S, Williams MR, Généreux P, et al. Efficacy and safety of postdilatation to reduce paravalvular regurgitation during balloon-expandable transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2013;6:85–91.CrossRefPubMed Daneault B, Koss E, Hahn RT, Kodali S, Williams MR, Généreux P, et al. Efficacy and safety of postdilatation to reduce paravalvular regurgitation during balloon-expandable transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2013;6:85–91.CrossRefPubMed
6.
go back to reference Lasa G, Gaviria K, Sanmartín JC, Telleria M, Larman M. Postdilatation for treatment of perivalvular aortic regurgitation after transcatheter aortic valve implantation. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2014;83:E112-118. Lasa G, Gaviria K, Sanmartín JC, Telleria M, Larman M. Postdilatation for treatment of perivalvular aortic regurgitation after transcatheter aortic valve implantation. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2014;83:E112-118.
7.
go back to reference Wang Y, Yu S, Qian D, Li J, Fang Z, Cheng W, et al. Anatomic predictor of severe prosthesis malposition following transcatheter aortic valve replacement with self- expandable Venus-a valve among pure aortic regurgitation: a multicenter retrospective study. Front Cardiovasc Med. 2022;9:1002071.CrossRefPubMedPubMedCentral Wang Y, Yu S, Qian D, Li J, Fang Z, Cheng W, et al. Anatomic predictor of severe prosthesis malposition following transcatheter aortic valve replacement with self- expandable Venus-a valve among pure aortic regurgitation: a multicenter retrospective study. Front Cardiovasc Med. 2022;9:1002071.CrossRefPubMedPubMedCentral
8.
go back to reference Adam M, Tamm A, Wienemann H, Unbehaun A, Klein C, Arnold M, et al. Transcatheter aortic valve replacement for isolated aortic regurgitation using a new self-expanding TAVR system. JACC Cardiovasc Interv. 2023;16:1965–73.CrossRefPubMed Adam M, Tamm A, Wienemann H, Unbehaun A, Klein C, Arnold M, et al. Transcatheter aortic valve replacement for isolated aortic regurgitation using a new self-expanding TAVR system. JACC Cardiovasc Interv. 2023;16:1965–73.CrossRefPubMed
9.
go back to reference JenaValve Technology, Inc. A study to assess safety and effectiveness of the JenaValve TrilogyTM heart valve system in the treatment of high surgical risk patients with symptomatic, severe aortic regurgitation (AR) [Internet]. clinicaltrials.gov; 2022 Sep [cited 2023 Sep 1]. Report No.: NCT04415047. Available from: https://clinicaltrials.gov/study/NCT04415047. JenaValve Technology, Inc. A study to assess safety and effectiveness of the JenaValve TrilogyTM heart valve system in the treatment of high surgical risk patients with symptomatic, severe aortic regurgitation (AR) [Internet]. clinicaltrials.gov; 2022 Sep [cited 2023 Sep 1]. Report No.: NCT04415047. Available from: https://​clinicaltrials.​gov/​study/​NCT04415047.
10.
go back to reference JenaValve Technology, Inc. THE ALIGN-AR TRIAL: safety and effectiveness/performance of the transfemoral JenaValve Pericardial TAVR System in the treatment of patients with symptomatic severe aortic regurgitation (AR) [Internet]. clinicaltrials.gov; 2022 Nov [cited 2023 Sep 1]. Report No.: NCT02732704. Available from: https://clinicaltrials.gov/study/NCT02732704. JenaValve Technology, Inc. THE ALIGN-AR TRIAL: safety and effectiveness/performance of the transfemoral JenaValve Pericardial TAVR System in the treatment of patients with symptomatic severe aortic regurgitation (AR) [Internet]. clinicaltrials.gov; 2022 Nov [cited 2023 Sep 1]. Report No.: NCT02732704. Available from: https://​clinicaltrials.​gov/​study/​NCT02732704.
Metadata
Title
Native aortic valve regurgitation: TAVR’s place in the PANTHEON
Author
Pradeep Narayan
Publication date
22-09-2023
Publisher
Springer Nature Singapore
Published in
Indian Journal of Thoracic and Cardiovascular Surgery / Issue 6/2023
Print ISSN: 0970-9134
Electronic ISSN: 0973-7723
DOI
https://doi.org/10.1007/s12055-023-01609-1

Other articles of this Issue 6/2023

Indian Journal of Thoracic and Cardiovascular Surgery 6/2023 Go to the issue